Cargando…
Evaluation of a Neurokinin-1 Antagonist in Preventing Multiple-day Cisplatin-induced Nausea and Vomiting
OBJECTIVE: To perform a prospective non-randomized comparison of the effectiveness and safety of combined neurokinin-1 antagonist aprepitant treatment with the standard multiple-day cisplatin regimen for the prevention of cisplatin-induced nausea and vomiting (CINV). METHODS: Patients being administ...
Autores principales: | Li, Quanfu, Wang, Wenjuan, Chen, Gang, Deng, Shuqin, Jiang, Caihong, Chen, Feng, Zhao, Jun, Li, Hui, Bai, Xiaojun, Hu, Yuliang, Da, Lenggaowa, Wu, Yungaowa, Jin, Gaowa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
De Gruyter Open
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5851005/ https://www.ncbi.nlm.nih.gov/pubmed/29577093 http://dx.doi.org/10.1515/med-2018-0005 |
Ejemplares similares
-
Olanzapine (5 mg) plus standard triple antiemetic therapy for the prevention of multiple-day cisplatin hemotherapy-induced nausea and vomiting: a prospective randomized controlled study
por: Gao, Jiali, et al.
Publicado: (2022) -
A randomized trial evaluating the association between related gene polymorphism and nausea and vomiting induced by cisplatin multi-day chemotherapy
por: Jin, Yilan, et al.
Publicado: (2023) -
A Comparison of the Efficacy of 5 mg Olanzapine and Aprepitant in the Prevention of Multiple-Day Cisplatin Chemotherapy-Induced Nausea and Vomiting
por: Liu, Guang, et al.
Publicado: (2022) -
The role of neurokinin-1 (substance P) antagonists in the prevention of postoperative nausea and vomiting
por: Okafor, Dionne, et al.
Publicado: (2017) -
Evolving role of neurokinin 1-receptor antagonists for chemotherapy-induced nausea and vomiting
por: Navari, Rudolph M, et al.
Publicado: (2018)